NextCure Receives Nasdaq Equity Deficiency Notice; January 4, 2027 Cure Deadline Set
NXTC has more than doubled off its 52-week low of $1.55 on light trading volume (0.4× avg).
Summary
Nasdaq notified NextCure on November 16, 2026 that its $5.5 million of stockholders' equity falls short of the $10 million minimum, giving it until January 4, 2027 to submit a compliance plan. The company is counting on the mid-December Avere merger closing to cure the deficiency.
Key Events · Legal and Risk Events · NXTC
-
Nasdaq Equity Deficiency Notice
On November 16, 2026, Nasdaq notified NextCure that it is not in compliance with Listing Rule 5450(b)(1)(A). Stockholders' equity of $5,503,000 as of September 30, 2026 fell below the $10.0 million minimum, and the company also failed the alternative market-value and total-assets/revenue tests.
-
January 4, 2027 Plan Deadline
Under Nasdaq Rule 5810(c)(2)(C), NextCure has 45 calendar days, until January 4, 2027, to submit a plan to regain compliance. The notice has no immediate effect on listing or trading.
-
Merger Is the Only Cure
NextCure expects the Avere Therapeutics merger to close in mid-December 2026, before the grace period ends, and believes that would restore compliance and may eliminate the need for a plan. If the merger slips, the company intends to submit a compliance plan.
-
December 9 Vote Is the Trigger
The S-4/A filed 2026-10-31 set a December 9, 2026 shareholder vote on the reverse merger. Failure to approve or close would leave the listing deficiency unresolved alongside going-concern doubt and $8.7 million of cash.
Analysis · NXTC · Life Sciences
The hard date is now set: NextCure must submit a compliance plan by January 4, 2027, because its $5.5 million of stockholders' equity sits well below the $10 million Nasdaq Global Select minimum. Management's entire fix is the Avere reverse merger, expected to close in mid-December 2026, ahead of the deadline. That makes the December 9 shareholder vote the single point of failure. Should the merger fail to win approval or close in time, NextCure would have to scramble for a plan while already carrying going-concern doubt and only $8.7 million of cash.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NXTC was trading at $7.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31M. The 52-week trading range was $1.55 to $15.74. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.